Program
Anti-CDH3/MMAE Antibody-drug Conjugate BC3195
Also written as “BC3195” and “Drug: BC3195 for Injection”.
Its studies are mostly in Neoplasm Metastasis, led by Biocity Biopharmaceutics.
Drug pageAnti-CDH3/MMAE Antibody-drug Conjugate BC3195: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocity Biopharmaceutics | 33 open or running | phase 2since Mar 5, 2026 | Jul 13, 2023 | Apr 30, 2027phase 1 · NCT06548672 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2023First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT05957471 · 27 planned · China
- Jul 11, 2024Phase 1 study in Neoplasm MetastasisNCT06548672 · 148 planned · United States
- Mar 5, 2026Phase 2 study in Locally Advanced or Metastatic Solid TumorsPhase 2 reachedNCT07469774 · 111 planned · China
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06548672
- Dec 31, 2027Primary completion: phase 2 study in Locally Advanced or Metastatic Solid TumorsNCT07469774
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the human tumor-associated antigen (TAA) cadherin-3 (CDH3; placental cadherin; P-cadherin), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07469774Locally Advanced or Metastatic Solid Tumors · China | 2 | Recruiting | Dec 31, 2027 | 111 |
| NCT06548672Neoplasm Metastasis · United States | 1 | Recruiting | Apr 30, 2027 | 148 |
| NCT05957471Locally Advanced or Metastatic Solid Tumors · China | 1 | Recruiting | Jun 2025 | 27 |
How it is read
Names in the registry
- “BC3195”, 2 entries
- “Drug: BC3195 for Injection”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.